Abstracts Archive - Page 162 of 2607 - ACR Meeting Abstracts

Abstract Number: 0757 • ACR Convergence 2025
The role of Methotrexate in the treatment of Giant Cell Arteritis: data from the ARTESER registry.
Pablo Muñoz-Martínez¹, Marta Domínguez-Álvaro², Lucia Otero³, Clara Moriano⁴, Julio Sánchez Martín⁵, Javier Narváez⁶, Eva Galíndez Agirregoikoa⁷, Javier Mendizábal⁸, lydia Abasolo Alcazar⁹, Javier Loricera¹⁰, Alejandro Muñoz¹¹, Santos Castañeda¹², rafeal Benito-Melero¹³, Carmen Larena¹⁴, Paula Estrada-Alarcón¹⁵, Carlos Galisteo¹⁶, Anne Riveros frutos¹⁷, Francisco Ortiz sanjuán¹⁸, Tarek Salman Montes¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Spanish Society of Rheumatology, Madrid, Spain, ⁴Hospital León, LEON, Castilla y Leon, Spain, ⁵Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Navarra Hospital, Pamplona, Spain, ⁹IdISSC. HCSC, Madrid, Madrid, Spain, ¹⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹¹Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ¹²Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹³MD, barcelona, Spain, ¹⁴Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ¹⁵Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹⁶Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ¹⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ¹⁹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common large-vessel vasculitis, and its cornerstone treatment is the use of corticosteroids (CS). Various therapies have been…
Abstract Number: 0583 • ACR Convergence 2025
Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
Raquel Granados¹, Jesús Eduardo Martín Salazar², María Ángeles Puche-Larrubia³, Pedro Ortiz Buitrago⁴, María Dolores López-Montilla⁵, Jerusalén Calvo⁶, Rafaela Ortega-Castro⁷, Montserrat Romero-Gómez⁸, Alejandro Escudero-Contreras⁹, Nuria Barbarroja¹⁰ and Clementina López Medina¹¹, ¹Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain, ²Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁸Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ⁹Reina Sofia University Hospital/Maimonides Institute of Biomedical Research of Córdoba(IMIBIC)/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Previous studies have identified subgroups of patients with psoriatic arthritis (PsA) based on the severity of the disease [1,2]. However, no analysis to date…
Abstract Number: 0616 • ACR Convergence 2025
Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
Juliana Silvatti¹, Livia Almeida Dutra², Larissa Araujo Duarte³, Andreza Salvio Lemos³, Helena Alessi⁴, Shaila Amorim Vieira², Gabriel D'Angelo Lacerda², LILIA ALVES MARIA ALVES MARIA⁴, Soniza Leon Alves³ and Cristiane Kayser⁴, ¹Universidade Federal de São Paulo, SAO PAULO, Sao Paulo, Brazil, ²Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Sao Paulo, Brazil, ³Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Universidade Federal de São Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) are common and frequently represent a diagnostic challenge due to its heterogeneous manifestations. Neurofilament light chain (NfL)…
Abstract Number: 0587 • ACR Convergence 2025
Regulatory Role of IL17 F in the Pannus Formation of Psoriatic Arthritis: A Comparative Study with IL-17A
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: IL-17A and IL-17F are the key inflammatory mediators in the IL-17 cytokine family (IL-17A to IL-17F). IL-17A is the widely recognized inflammatory cytokine in…
Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
J. Michelle Kahlenberg¹, Victoria Werth², Joerg Wenzel³, John Schwarz⁴, Jinqi Liu⁴ and Brandon Johnson⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
Abstract Number: 0628 • ACR Convergence 2025
Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus
Panagiotis Garantziotis¹, Dionysis Nikolopoulos², Spyridon Katechis³, Alp Temiz⁴, Danae-Mona Nöthling¹, Christina Adamichou⁵, Prodromos Sidiropoulos⁶, Georg Schett⁷, Fanouriakis Antonis³, Dimitrios Boumpas⁸ and George Bertsias⁹, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical School University of Crete, Heraklion, Greece, Heraklion, Germany, ⁶Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ⁹Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece
Background/Purpose: Organ damage drives morbidity and mortality in systemic lupus erythematosus (SLE), yet no validated tools exist to predict early damage. We aimed to develop…
Abstract Number: 0875 • ACR Convergence 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield¹, Ricardo Galimberti², Adelaide Hebert³, Wen-Hui Wang⁴, Jennifer Soung⁵, Nina Magnolo⁶, John Browning⁷, Angela Moore⁸, Mark Lebwohl⁹, Dagmar Wilsmann-Theis¹⁰, Joseph F Merola¹¹, Georgios Kokolakis¹², Dariusch Mortazawi¹³, Parbeer Grewal¹⁴, Megan Miller¹⁵, Joseph Cafone¹⁶, Shu Li¹⁷, Gigi Jiang¹⁷, Fabio Nunes¹⁷, Cynthia DeKlotz¹⁸ and Amy Paller¹⁹, ¹University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, ²Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ³University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, ⁴Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), ⁵Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁶University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁷Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, ⁸Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹³Clinical Research Center, Remscheid, Germany, Remscheid, Germany, ¹⁴University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, ¹⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ¹⁶Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ¹⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁸Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL
Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
Abstract Number: 0768 • ACR Convergence 2025
Veteran Rehabilitation, Physical Therapy Care Delivery, and Outcomes after Total Knee Arthroplasty
Nina Carson¹, Jeremy Graber², Shane O'Malley³, Dennis Hanse⁴, Amy Peters⁵, Jennifer Stevens-Lapsley⁶ and Michael Bade⁶, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado Anschutz Medical Campus & the VA Denver-Seattle Center of Innovation, Aurora, CO, ³Eastern Colorado Health Care System, Aurora, CO, ⁴Eastern Colorado Health Care System & University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Eastern Colorado Health Care System and University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶University of Colorado Anschutz Medical Campus & Eastern Colorado Health Care System, Aurora, CO
Background/Purpose: Compared to the general population, Veterans have higher prevalence of knee osteoarthritis, comorbidities, activities of daily living limitations, and healthcare utilization following total knee…
Abstract Number: 0594 • ACR Convergence 2025
Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways
Holme Vestin¹, Nina Oparina¹, Maija-Leena Eloranta¹, Martina Frodlund², Iva Gunnarsson³, Chrisopher Sjöwall², Elisabet Svenungsson⁴, Lars Rönnblom¹, Juliana Imgenberg-Kreuz¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The pathogenesis of SLE involves genetic, environmental and epigenetic factors (1). Increased levels of Bisphenol A (BPA) have been observed in the urine of…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0662 • ACR Convergence 2025
Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
Marta Mosca¹, Karen H. Costenbader², Amit Saxena³, Michelle Petri⁴, Andrea Rubbert-Roth⁵, Karim Masri⁶, Christopher Saffore⁷, Ling Cheng⁸ and Joan Merrill⁹, ¹University of Pisa, Pisa, Pisa, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵Division of Rheumatology and Immunology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., waukegan, IL, ⁸AbbVie, North, IL, ⁹Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK
Background/Purpose: Clinical and immunological manifestations of systemic lupus erythematosus (SLE) vary widely across patients, complicating diagnosis and treatment (1,2). Upadacitinib (UPA), an oral selective JAK…
Abstract Number: 0638 • ACR Convergence 2025
Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
Takehiro Nakai¹, Sho Fukui², Yukihiko Ikeda³, Masei Suda⁴, Hiromichi Tamaki¹, mitsumasa kishimoto⁵ and Masato Okada⁶, ¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ³St Luke's international hospital in Japan, Tokyo, Japan, ⁴Suwa Central Hospital, Nagano, Japan, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with an increased risk of chronic kidney disease (CKD), avascular necrosis (AVN), and mortality. Despite…
Abstract Number: 0771 • ACR Convergence 2025
Radiographic Knee Osteoarthritis and Corticosteroid Injection Use: The Moderating Role of Physical Activity
Sydney Liles¹, Jennifer Copson², Daniel K. White¹ and Jason Jakiela³, ¹University of Delaware, Newark, DE, ²University of Delaware, Wilmington, DE, ³Winston-Salem State University, Winston-Salem, NC
Background/Purpose: Knee osteoarthritis (OA) is a chronic disease with no current cure and a leading cause of disability among adults. Treatment for knee OA focuses…
Abstract Number: 0682 • ACR Convergence 2025
Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study
Alex Luta¹, Saloni Mitchell² and Virginia Steen³, ¹Hospital for Special Surgery, New York, NY, ²Mount Sinai West and Morningside, New York, NY, ³Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
Abstract Number: 0674 • ACR Convergence 2025
Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis
Ian Odell¹, Crystal Cheung¹, Megan Wu², Stephanie Perez³, Agrani Dixit⁴, Cassandra van Horn³, Muhammad Hamdan⁵, Baran Gunes⁶, Sophia Kujawski⁷, Hyojeong Lee³, Annie Wang³, Denise Esserman⁸, Michael Zamani⁹, F. Perry Wilson³, John Onofrey³, Xenophon Papademetris³ and Monique Hinchcliff¹⁰, ¹Yale University School of Medicine, New Haven, CT, ²Yale University School of Medicine, Greenville, ³Yale University School of Medicine, New Haven, ⁴Yale School of Medicine, New Haven, CT, ⁵Yale University School of Medicine, Mansfield, ⁶Yale University School of Medicine, Pompton Plains, NJ, ⁷The George Washington University, New Haven, CT, ⁸Yale University School of Public Health, New Haven, ⁹Independent Statistician, Washington D.C., ¹⁰Yale School of Medicine, Westport, CT
Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].